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Summary
Prevalence of hypercalciuria is markedly increased in patients
with calcium kidney stones, and recently it has been demon-
strated that the risk to produce stones is positively related with
the levels of calcium excretion in general population. The stone-
promoting effect of hypercalciuria depends on the unusually
high calcium concentrations in urine and tubular fluid, which fa-
vor calcium salt precipitation. However, the specific role of calci-
um in the pathogenetic pathway leading to stone formation has
not been elucidated and it is unclear whether initial events of
this process develop in tubules or in papillary interstitium. 
Nephrocalcinosis occurs in the course of many hereditary or
acquired disorders having hypercalciuria as the common alter-
ation and can progressively damage kidney function. In spite of
the relevance of hypercalciuria for nephrocalcinosis, the specif-
ic effect of calcium in its development is yet unknown.
An increased frequency of hypercalciuria has also been
recorded among patients with arterial hypertension. It has
been hypothesized that a body calcium deficiency is induced
by hypercalciuria and leads to the elevation of blood pressure.
This may be true in a subgroup of patients, while hypercalci-
uria is likely to occur more commonly in patients with volume-
dependent hypertension.
Irrespective of its possible causal role, hypercalciuria may
predict individual susceptibility to stones, nephrocalcinosis or
arterial hypertension. Measurement of 24 hour calcium excre-
tion could become an instrument to identify subjects predis-
posed to these disorders.
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Introduction
Primary hypercalciuria is a defect of calcium metabolism, char-
acterized by increased 24 hour urinary calcium excretion which
is not justified by any apparent metabolic alteration (1). Its
prevalence is 5-10% in the general population (1), but is signifi -
cantly higher in patients with calcium kidney stones (2),
nephrocalcinosis (3), arterial hypertension (4) and osteoporosis
(5). 
Primary hypercalciuria has a familial distribution displaying a
complex transmission pattern due to a polygenic substrate (6).
In addition to the family history, large body mass and high in-
take of animal proteins and salt predispose to hypercalciuria (7,
8). Therefore, primary hypercalciuria appears as a multifactori-
al disorder determined by the interaction of different genetic
and environmental factors (Fig. 1). 
Urinary wastage of calcium can give rise to problems maintain-
ing proper calcium balance; whereas, high calcium concentra-
tion in urine may predispose to nephrolithiasis and nephrocalci-
nosis. 
Kidney as a cause of primary hypercalciuria 
In most of patients, primary hypercalciuria results from an in-
crease of intestinal calcium absorption (absorptive hypercalci-
uria) (2,9). In less than 5% of patients, primary hypercalciuria
may be caused by a primary defect in tubular calcium reab-
sorption (renal hypercalciuria) (2,10). These different forms of
hypercalciuria are clinically distinguished with the measure-
ments of fasting calcium excretion and plasma PTH. In absorp-
tive hypercalciuria, fasting calcium excretion is normal, while
circulating levels of PTH are low. In renal hypercalciuria, both
fasting calcium excretion and circulating PTH are high (10). In
spite of these simple criteria, the real mechanisms leading to
hypercalciuria remain unclear and around one-third of patients
remain unclassifiable because they exhibit fasting hypercalci-
uria and normal plasma PTH (10). Furthermore, contrarily to
expectations, patients with absorptive hypercalciuria often have
a deficit in bone mineral density, similar to that observed in re-
nal hypercalciuria (11,12). Recently, we found that hypercalci-
uric stone-forming women with low bone mineral density at ver-
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F i g u r e1 - Primary hypercalciuria is as a multifactorial disorder deter-
mined by the interaction of different genetic and environmental factors.
Protein and sodium excess in diet increases urinary calcium excretion
through different mechanisms. Genetic factors work at different pheno-
type levels and make hypercalciuric subjects more sensitive to stimuli
inducing calcium excretion.
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tebral sites presented the highest values of intestinal calcium
absorption (11). This observation suggests that the defect
causing hypercalciuria could be expressed in bones and intes-
tine, where it could activate calcium absorption and bone me-
tabolism and ultimately increase calcium excretion. Many pro-
teins with a relevant role in calcium metabolism, like calcium-
sensing receptor, vitamin D receptor or calcium pump, are ex-
pressed in bone, tubular and enteral cells. In case of their alter-
ation, the effect on calcium excretion should result from the
combination of their influences in bones, intestine and kidney.
Therefore, in some groups of patients, pathogenesis of hyper-
calciuria could be more complex than proposed till now.
Urinary alterations associated to primary hypercalciuria
Increased excretions of sodium, sulphate, urate, urea and
phosphate may be found in hypercalciuric patients and also in
their relatives and were justified with a high dietary intake of
these substances or their precursors (13). Further studies ex-
ploring the effect of nutrients on ion excretion displayed that
animal proteins and sodium are important determinants of uri-
nary calcium and that their excess in diet increases the values
of excreted calcium (7,8,14,15). 
Dietary sodium load favors excretion of calcium by a reduction
of its tubular reabsorption (7,14), but this effect can manifest it-
self only when sodium is ingested as chloride salt, whereas it
does not occur after a sodium-bicarbonate load (16). 
A diet rich in animal proteins can increase the urinary excretion
of urea, urate, sulphate, protons and calcium (15). Chronic load
of acids, secondary to the catabolism of methionine and other
acid amino acids, is able to decrease tubular calcium reabsorp-
tion and to release calcium ions from bone tissue, thus con-
tributing to the increase of calcium excretion (14). In addition,
chronically high protein intake may induce renal hypertrophy,
which may up-regulate calcitriol synthesis. The consequent ac-
tivation of intestinal calcium absorption and inhibition of PTH
secretion may result in the development of hypercalciuria (8,
14). 
All these findings suggest that chronic overconsumption of
sodium-chloride and animal proteins predisposes to hypercalci-
uria. However, it remains unexplained why only some subjects
can abnormally increase their calcium excretion as a conse-
quence of a large ingestion of proteins and sodium-chloride. It
is likely that genetic factors make hypercalciuric subjects more
sensitive to stimuli inducing calcium excretion (Fig. 1). 
Hypercalciuria and calcium stone production
Kidney stone disease may be considered as the main compli-
cation of hypercalciuria. Despite the amount of research, the
first evidence that hypercalciuric subjects are predisposed to
kidney stones was recently provided in a work, displaying that
the risk to produce stones increased with calcium excretion in
general population (17). Previous studies had limited their ob-
servation to the higher frequency of hypercalciuria in calcium
stone forming patients and the larger calcium excretion in re-
lapsing compared to non-relapsing stone formers (18). 
In spite of these findings, the real role of calcium in stone for-
mation has not been yet understood. Calcium stone-promoting
activity may be due to the effect of calcium ions on urinary sta-
bility and saturation for calcium salts. However, when tested in
vitro, the effect of calcium ions on the activity product of calci-
um-oxalate or calcium-phosphate was much less remarkable
than that of phosphate, oxalate or water; thus, calcium concen-
tration did not appear as the main determinant of salt solubility
(19). Therefore, other aspects of calcium activity in stone for-
mation have been explored. It was observed that the intrinsic
urinary power to inhibit salt precipitation decreased when calci-
um was added to urine. This effect was attributed to calcium-in-
duced alterations in molecular structure of Thamm-Horsfall pro-
tein, that reduced its efficacy to inhibit calcium-oxalate and cal-
cium-phosphate crystal nucleation and growth (20).
Uncertainty about the role of calcium is also justified by the fact
that the pathogenetic mechanism for stone production is un-
known. The current theories hypothesize that initial events in
stone formation can develop in tubules or, alternatively, in pap-
illary interstitium. According to the tubular theory (Fig. 2), a
stone can develop from crystal agglomerates retained within
the lumen of a renal tubule (21). Physical-chemical characteris-
tics of tubular fluid can promote the precipitation of calcium-
phosphate within the ascending Henle’s loop and calcium-ox-
alate in the collecting tubule (21). Crystals can grow and aggre-
gate in supersaturated fluids and can be retained within the
tubular lumen due to their capability to adhere to the tubular
wall. Studies in animals showed that oxalate, under the form of
ions or crystals, can cause tubular cell injury, necrosis or apop-
tosis with release of cell debris in tubular lumen and exposure
of basement membrane to the tubular fluid. These events may
b  crucial for macroaggregate development and stone forma-
tion, because crystals can easily attach to the injured tubular
wall and calcium-oxalate can precipitate on cell debris, espe-
cially membrane fragments rich of phospholipids, even in the
presence of stable urine (21-23). The final pathway for stone
production may be the retention of a crystal macroagglomerate
within papillary Bellini’s ducts, which may become a stone after
ulceration of the papilla and its exposition to the urinary tract
(24). 
The alternative and recently renewed theory hypothesizes that
papillary interstitium is the place where kidney stone is pro-
duced (24,25). Histological studies showed that calcium phos-
phate deposits (Randall’s plaques) are typically found in papil-
lary interstitium of patients with idiopathic calcium kidney
stones (25). These plaques apparently originated from the
basement membrane of thin descending loops of Henle’s loop
and developed into interstitium surrounding primarily tubules,
vasa recta and Bellini’s ducts. They were suburothelial, but
could erode urothelium and erupt into calices (24), becoming
an area where a calcium oxalate stone may develop. No intra-
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F i g u r e2 - The tubular theory hypothesizes that a stone can develop
from crystal agglomerates retained within the tubular lumen. A nodular
macroaggregate retained in a Bellini’s duct may become a stone after
ulceration of the papilla. Different steps in stone formation are de-
sc ibed in the figure.
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cellular or subcellular crystals were observed at kidney micro-
scopic examination (25). Deposits were composed by hydrox-
yapatite with a small component of calcium carbonate. 
In the same study, histological analysis of kidney papilla was
also performed in patient with stones secondary to ileo-intesti-
nal by-pass (25). Nodular apatite aggregates were detected
within collecting ducts and were associated to cell injury, while
no deposits were found on tubular basement membrane.
Therefore, these different papillary pictures suggest that an in-
terstitial stone pathogenesis occurs in patients with idiopathic
calcium stones and a tubular pathogenesis in those with ileo-
intestinal by-pass. 
These two theories do not describe the role of hypercalciuria in
stone production. Although not generally acknowledged, it is
likely that its role depends on calcium concentrations in urine
or renal interstitial fluid, which change in function of the calcium
load provided by foods. Thus, calcium stone promoting activity
may be enhanced after food intake, when the amount of filtered
calcium and its tubular load raise. Postprandial overload may
increase delivery of calcium to distal tubule; in outer medulla,
calcium ions are reabsorbed and then carried into deep medul-
la by vasa recta (25). In hypercalciuric patients, this process
occurs in the presence of unusually high calcium concentration
and much more calcium may reach papilla. In addition to calci-
um, also a tubular overload of phosphate occurs after a meal,
so that the stability of fluids for calcium and phosphate may be
impaired in papillary interstitium or tubules (25). The formation
of a Randall’s plaque or a nodular magroaggregate in Bellini’s
duct may start the final process of stone formation, but it re-
mains unexplained how calcium-oxalate stones may develop
from interstitial hydroxyapatite or tubular calcium-phosphate
deposits (21-23). 
Hypercalciuria and nephrocalcinosis
Renal deposition of calcium-phosphate or calcium-oxalate re-
sults in nephrocalcinosis. This disorder is more frequently
found in children and preterm newborns and deposits are more
frequently composed by apatite and begins within medulla. In
rare patients with primary hyperoxaluria (type 1 or 2) deposits
are cortical and composed by calcium-oxalate. 
Nephrocalcinosis may occur in the course of many hereditary
tubular disorders having hypercalciuria as the common alter-
ation: Dent’s disease, Bartter’s disease (type 1 and 2), distal
tubular acidosis, primary hypomagnesemia-hypercalciuria-
nephrocalcinosis syndrome. These tubular disorders are mono-
genic and were found in 33% of newborn with nephrocalcinosis
(26). Conversely, iatrogenic causes were responsible of 30-
50% of infant nephrocalcinosis (26). Furosemide and vitamin D
are the most frequently implicated drugs, probably due to their
capability to increase calcium excretion (27,28). Nephrocalci-
nosis was also associated to the use of gentamicine, extreme
prematurity and severe respiratory disease (29). Vitamin D,
with calcium or phosphate salts, is used to maintain normal
plasma concentrations of calcium and phosphate in children
with hypoparathyroidism or renal rickets, in their different
forms. Because these patients are predisposed to lose calcium
in urine, therapy with bivalent ions and vitamin D increases
their calcium excretion to an extent that greatly amplifies the
risk for renal calcium-phosphate precipitation. 
Hypercalciuria was observed in 34% of newborns with nephro-
calcinosis (27), but increased oxalate and urate excretions and
decreased citrate excretion were also described (29). Plasma
calcium concentrations, calcium and phosphate intake were
found increased in newborns with nephrocalcinosis (27).
Nephrocalcinosis can solve in 50% of infants, but resolution is
less probable in children with hypercalciuria (30). 
In adults, nephrocalcinosis usually occurs in patients with pri-
mary hyperparathyroidism or sarcoidosis or in patients chroni-
cally taking calcium or phosphate salts and vitamin D for con-
trol of hypocalcemia or hypophosphatemia. In addition, nephro-
calcinosis can develop in patients with medullary sponge kid-
ney and severe infectious or ischemical diseases of kidney.
Nephrocalcinosis can progressively damage kidney function,
impairing glomerular filtration rate and urinary concentration
capacity. Deterioration of renal function may be slight with time,
but it is correlated with the degree of nephrocalcinosis and to
severity of the underlying disorder (30). Nephrolithiasis may
complicate nephrocalcinosis and was reported in 14% of chil-
dren (27). It may occur when an interstitial deposit erupts into
urinary tract and becomes a site for salt deposition open to the
urinary tract (24).
Mechanisms leading to interstitial calcium phosphate deposits
are not known. Similar to nephrolithiasis, in nephrocalcinosis
there may be an imbalance between inhibitors and promoters
of calcium salt precipitation (26). Few models of experimental
nephrocalcinosis have been tested. Anoxic incubation of rat re-
nal cortex gave rise to calcification that began at the inner sur-
face of cellular membranes and in mitochondria. Deposits were
nitially constituted by amorphous calcium-phosphate, while lat-
er by apatite (31). Npt2 knock-out rats, in which sodium-phos-
phate carrier (Npt2) was disrupted, developed nephrocalci-
nosis, due to deposition of apatite diffusely placed in renal cor-
tex, medulla and papilla. The presence of calcifications was as-
sociated with tubular cell expression of osteopontin which may
have a protective role (32). 
Physical-chemical factors can be implicated in the appearance
of calcification within medullary interstitium: high concentration
of salts, bundle disposition of tubules and vasa recta, slow
blood circulation and countercurrent mechanism may make
medulla the preferential place for salt deposition.
Hypercalciuria is the alteration most frequently detected in pa-
tients with nephrocalcinosis. Due to this point, hypercalciuria
has been proposed as a cause of nephrocalcinosis, but the
specific role of calcium in mechanisms for tissue salt deposition
remains unknown.
Hypercalciuria and arterial hypertension
An alteration of calcium metabolism has been hypothesized in
p tients with arterial hypertension and could be revealed by hy-
percalciuria (33). Many strains of hypertensive rats are hyper-
calciuric, suggesting that hypercalciuria and hypertension may
hare a common genetic substrate (34). High calcium excretion
can be found also in hypertensive patients and the prevalence
of hypercalciuria among these patients was around 35% (3,
33). To explain their association, it has been hypothesized that
hypercalciuria may predispose subjects to hypertension induc-
ing a condition of chronic calcium deficiency (35). This hypoth-
esis was supported by studies displaying that the prevalence of
hypertension was low in populations with high dietary calcium
intake (36). However, the study of anti-hypertensive effect of
oral calcium supplements gave controversial results in double-
blind trials (37,38). Meta-analyses of these trials confirmed an
hypotensive effect of calcium supplements on systolic blood
pressure, but the degree of its effect was too small to propose
the use of calcium as an anti-hypertensive drug. These meta-
analyses also concluded that calcium anti-hypertensive activity
could be exerted only in specific responsive subgroups of pa-
tients (39). 
The supposed pathogenetic link between hypercalciuria and
hypertension has not been yet explained. Researchers ad-
dressed their studies to the analysis of cell calcium transport in
kidney or vascular cells, but these studies provided no defini-
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tive results, although a reduction of calcium transport was
recorded in erythrocytes and kidney tubular cells (40-41). Alter-
natively, hypercalciuria could be considered as an epiphenom-
enon, occurring in patients with volume-dependent hyperten-
sion, characterized by hypertensive response to sodium-chlo-
ride load and low plasma renin activity (42). This second possi-
bility is today felt by the researchers as more likely in a large
part of hypertensive patients.
Conclusions
Clinical findings indicate that primary hypercalciuria predispos-
es affected subjects to nephrolithiasis and nephrocalcinosis,
even though its specific pathogenetic role has not been eluci-
dated in both disorders. The effect of hypercalciuria is likely to
depend on unusually high calcium concentrations in urine or
tubular fluid of patients. When calcium concentrations exceed
the threshold for precipitation, calcium salts may be deposited
in renal interstitium or tubular lumen. Salt precipitation may be
easier in kidney papilla, due to its particular architecture and
physical-chemical characteristics of its fluids in tubules and in-
terstitium. 
The pathogenesis of nephrocalcinosis or nephrolithiasis may
be similar in hypercalciuric subjects. This possibility is indicated
by the presence of both defects in patients with tubular disor-
ders and by the presence of nephrolithiasis in heterozygous
relatives of homozygous patients with hypomagnesemia-hyper-
calciuria-nephrocalcinosis syndrome or other tubular disorders
(43). However, other factors in addition to hypercalciuria may
be needed to cause the appearance of nephrocalcinosis or
nephrolithiasis. 
Irrespective to its causal role, the presence of hypercalciuria
may be clinically relevant because it may predict individual sus-
ceptibility to stones or other disorders like arterial hypertension
or osteoporosis. Epidemiological studies have to confirm the
real predictive power of hypercalciuria, but in the case of posi-
tive results, the measurement of 24 hour calcium excretion
should become an instrument to identify subjects susceptible to
these disorders and to prevent them. 
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